サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1692191

細胞リプログラミング市場- 世界の産業規模、シェア、動向、機会、予測、技術別、用途別、エンドユーザー別、地域別、競合別セグメント、2020-2030F

Cell Reprogramming Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Technology, By Application, By End User, By Region & Competition, 2020-2030F

出版日
ページ情報
英文 182 Pages
納期
2～3営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=144.06円

こちらのレポートには、数時間（ご購入金額の10%）分のアナリストへの質問／追加調査サービスが含まれております。

細胞リプログラミング市場- 世界の産業規模、シェア、動向、機会、予測、技術別、用途別、エンドユーザー別、地域別、競合別セグメント、2020-2030F
出版日: 2025年03月24日
発行: TechSci Research
ページ情報: 英文 182 Pages
納期: 2～3営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

細胞リプログラミングの世界市場は、2024年には3億2,545万米ドルとなり、2030年までのCAGRは8.14%で、予測期間中に目覚ましい成長を遂げると予測されています。

細胞リプログラミングは、バイオテクノロジーと再生医療における革命的な分野として登場しました。細胞リプログラミングは、通常の細胞を多能性幹細胞に変換したり、ある細胞タイプを別の細胞タイプに直接変換したりすることが期待されており、疾患モデリング、創薬、再生療法に前例のない機会を提供しています。世界の細胞リプログラミング市場は、技術の進歩、研究資金の増加、革新的なヘルスケアソリューションへの需要の高まりにより、着実に成長しています。

市場概要
予測期間 2026-2030
市場規模：2024年 3億2,545万米ドル
市場規模：2030年 5億1,635万米ドル
CAGR：2025年～2030年 8.14%
急成長セグメント m RNAリプログラミング
最大市場 北米

細胞リプログラミングは、成熟した特殊化した細胞を、より原始的な状態、しばしば胚性幹細胞に似た状態に変換することを含みます。このプロセスは様々な技術によって達成することができるが、最もよく知られているのは、人工多能性幹細胞（iPSC）リプログラミングと直接系統変換です。iPSCリプログラミングによって、科学者は成体細胞を取り出し、その発生時計を巻き戻し、多能性を持たせて様々な細胞型に分化できるようにすることができます。これとは対照的に、直接系列変換は多能性の段階をスキップし、皮膚細胞を神経細胞に変えるなど、ある細胞型を別の細胞型に直接変換します。

世界の細胞リプログラミング市場は、多様なアプリケーションによって牽引されています。細胞リプログラミングは、移植用の患者特異的で機能的な細胞の作製を可能にし、拒絶反応のリスクを低減することで、再生医療に革命をもたらす可能性を秘めています。研究者は、多能性幹細胞を用いて疾患特異的な細胞株を作製し、様々な疾患の分子メカニズムを研究し、潜在的な薬剤候補をスクリーニングすることができます。細胞リプログラミングは、医薬品スクリーニングや毒性試験において重要な役割を果たし、動物実験の必要性を減らし、医薬品開発を加速します。多能性幹細胞は個々の患者から作製できるため、個別化治療や治療計画の開発が可能になります。

市場促進要因

慢性疾患の有病率の上昇が世界の細胞リプログラミング市場を牽引

主な市場課題

技術的複雑性

主要市場動向

技術の進歩

目次

第1章 概要

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 顧客の声

第5章 世界の細胞リプログラミング市場展望

  • 市場規模・予測
    • 金額別
  • 市場シェア・予測
    • 技術別（センダイウイルスベース、mRNAリプログラミング、その他）
    • 用途別（調査、治療）
    • エンドユーザー別（調査・学術機関、バイオテクノロジー・製薬会社、病院・クリニック、その他）
    • 地域別
    • 企業別（2024年市場上位5社のシェア）
  • 市場マップ
    • 技術別
    • 用途別
    • エンドユーザー別
    • 地域別

第6章 北米の細胞リプログラミング市場展望

  • 市場規模・予測
  • 市場シェア・予測

第7章 欧州の細胞リプログラミング市場展望

  • 市場規模・予測
  • 市場シェア・予測

第8章 アジア太平洋地域の細胞リプログラミング市場展望

  • 市場規模・予測
  • 市場シェア・予測

第9章 南米の細胞リプログラミング市場展望

  • 市場規模・予測
  • 市場シェア・予測

第10章 中東・アフリカの細胞リプログラミング市場展望

  • 市場規模・予測
  • 市場シェア・予測

第11章 市場力学

  • 促進要因
  • 課題

第12章 市場動向と発展

  • 最近の動向
  • 合併と買収
  • テクノロジーの発表

第13章 競合情勢

  • Allele Biotechnology co. ltd.
  • ALSTEM, INC
  • Applied Biological Materials Inc.
  • Axol Bioscience Ltd.
  • Fujifilm Cellular Dynamics inc.
  • Lonza Group AG
  • Mogrify inc.
  • REPROCELL Inc.
  • Stemnovate Limited
  • Thermo Fisher Scientific Inc.

第14章 戦略的提言

第15章 調査会社について・免責事項

目次
Product Code: 17395

The Global Cell Reprogramming Market was valued at USD 325.45 million in 2024 and is anticipated to project impressive growth in the forecast period with a CAGR of 8.14% through 2030. Cell reprogramming has emerged as a revolutionary field in biotechnology and regenerative medicine. It holds the promise of transforming ordinary cells into pluripotent stem cells or directly converting one cell type into another, offering unprecedented opportunities for disease modeling, drug discovery, and regenerative therapies. The global cell reprogramming market has been steadily growing, driven by advancements in technology, increasing research funding, and a growing demand for innovative healthcare solutions.

Market Overview
Forecast Period2026-2030
Market Size 2024USD 325.45 Million
Market Size 2030USD 516.35 Million
CAGR 2025-20308.14%
Fastest Growing Segmentm RNA Reprogramming
Largest MarketNorth America

Cell reprogramming involves the conversion of mature, specialized cells into a more primitive state, often akin to embryonic stem cells. This process can be achieved through various techniques, with the most well-known being induced pluripotent stem cell (iPSC) reprogramming and direct lineage conversion. iPSC reprogramming allows scientists to take adult cells and rewind their developmental clock, making them pluripotent and capable of differentiating into various cell types. In contrast, direct lineage conversion skips the pluripotent stage, directly converting one cell type into another, such as turning skin cells into neurons.

The global cell reprogramming market is driven by a diverse range of applications. Cell reprogramming has the potential to revolutionize regenerative medicine by enabling the creation of patient-specific, functional cells for transplantation, thereby reducing the risk of rejection. Researchers can use pluripotent stem cell to create disease-specific cell lines, allowing them to study the molecular mechanisms of various diseases and screen potential drug candidates. Cell reprogramming plays a crucial role in drug screening and toxicity testing, reducing the need for animal testing and accelerating drug development. Pluripotent stem cell can be generated from individual patients, enabling the development of personalized therapies and treatment plans.

Key Market Drivers

Rising Prevalence of Chronic Diseases is Driving the Global Cell Reprogramming Market

The global healthcare landscape is witnessing a paradigm shift as chronic diseases continue to rise in prevalence. Diseases such as diabetes, cardiovascular disorders, neurodegenerative conditions, and cancer have become increasingly common, posing a significant challenge to healthcare systems worldwide. In response to this growing health crisis, the field of cell reprogramming is emerging as a promising frontier for addressing chronic diseases. The global cell reprogramming market is gaining momentum as researchers and biotechnology companies explore innovative ways to harness the regenerative potential of cells. For instance, the International Agency for Research on Cancer (IARC) projects that by 2040, the global cancer burden will rise to 27.5 million new cases and 16.3 million cancer-related deaths, largely due to population growth and aging. Additionally, an August 2022 article in the Radiation journal featured research by a Kindai University scientist in Japan exploring the optimal use of Radium-223 therapy for Metastatic Castration-Resistant Prostate Cancer. The study indicated that early administration of Ra-223 significantly improved overall survival (OS), highlighting potential advantages of using Ra-223 before novel hormonal or anticancer treatments.

Key Market Challenges

Technical Complexity

One of the primary challenges in the field of cell reprogramming is the technical complexity involved in generating high-quality iPSCs. Reprogramming adult cells into pluripotent stem cells is a delicate process that requires precise manipulation of cellular factors. Researchers must carefully select reprogramming methods, optimize culture conditions, and monitor cell differentiation to ensure the reliability and safety of iPSCs. This technical complexity not only demands considerable expertise but also makes the production of iPSCs time-consuming and costly.

Key Market Trends

Technological Advancements

The field of regenerative medicine has been revolutionized in recent years, thanks to significant advancements in cell reprogramming technology. Cell reprogramming, a process that involves resetting the identity of mature cells to a pluripotent state, has opened new avenues for the treatment of various diseases and the development of personalized medicine. As technological innovations continue to accelerate, the global cell reprogramming market is experiencing unprecedented growth. The advent of CRISPR-Cas9 technology has significantly enhanced the precision and efficiency of cell reprogramming. Researchers can now edit specific genes within cells, eliminating potential genetic mutations that may hinder the successful reprogramming process. This innovation has accelerated the production of high-quality iPSCs for various applications.

Automation systems and high-throughput screening platforms have streamlined the cell reprogramming process. This allows for the rapid generation of iPSCs in larger quantities, making them more accessible for research and clinical use. Automated systems also reduce the risk of contamination and human error, ensuring consistent and reliable results. Technological advancements in 3D bioprinting and the development of organoids have expanded the possibilities of cell reprogramming. These techniques enable the creation of complex, tissue-like structures from iPSCs, paving the way for more advanced disease modeling and drug testing. Artificial intelligence and machine learning algorithms have become integral in analyzing and interpreting large datasets generated from cell reprogramming experiments. These tools help identify novel factors and pathways involved in reprogramming, leading to more efficient and targeted approaches. Traditional methods of introducing reprogramming factors into cells often relied on viral vectors, which carried risks of genomic integration and mutagenesis. Non-viral delivery systems, such as synthetic RNA and protein-based approaches, have emerged as safer alternatives, improving the overall safety profile of cell reprogramming.

The global cell reprogramming market is witnessing remarkable growth, driven by these technological advancements and their applications. Pharmaceutical companies are increasingly investing in iPSC-based drug discovery and toxicity testing, while academic institutions are using iPSCs to study various diseases, including neurodegenerative disorders, heart disease, and cancer. Furthermore, the field of regenerative medicine is moving closer to the realization of personalized therapies. iPSCs derived from a patient's own cells can be reprogrammed and differentiated into specific cell types, offering the potential for individualized treatments and reduced risk of immune rejection.

Key Market Players

  • Allele Biotechnology co. ltd.
  • ALSTEM, INC
  • Applied Biological Materials Inc.
  • Axol Bioscience Ltd.
  • Fujifilm Cellular Dynamics inc.
  • Lonza Group AG
  • Mogrify inc.
  • REPROCELL Inc.
  • Stemnovate Limited
  • Thermo Fisher Scientific Inc

Report Scope:

In this report, the Global Cell Reprogramming Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Cell Reprogramming Market, By Technology:

  • Sendai Virus-based
  • mRNA Reprogramming
  • Others

Cell Reprogramming Market, By Application:

  • Research
  • Therapeutic

Cell Reprogramming Market, By End user:

  • Research & Academic Institutes
  • Biotechnology & Pharmaceutical Companies
  • Hospitals & Clinics
  • Others

Cell Reprogramming Market, By Region:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Cell Reprogramming Market.

Available Customizations:

Global Cell Reprogramming market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validations
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Cell Reprogramming Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Technology (Sendai Virus-based, mRNA Reprogramming, Others)
    • 5.2.2. By Application (Research, Therapeutic)
    • 5.2.3. By End user (Research & Academic Institutes, Biotechnology & Pharmaceutical Companies, Hospitals & Clinics, Others)
    • 5.2.4. By Region
    • 5.2.5. By Company (Shares of Top 5 Market Players, 2024)
  • 5.3. Market Map
    • 5.3.1. By Technology
    • 5.3.2. By Application
    • 5.3.3. By End user
    • 5.3.4. By Region

6. North America Cell Reprogramming Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Technology
    • 6.2.2. By Application
    • 6.2.3. By End user
    • 6.2.4. By Country
      • 6.2.4.1. United States Cell Reprogramming Market Outlook
        • 6.2.4.1.1. Market Size & Forecast
        • 6.2.4.1.1.1. By Value
        • 6.2.4.1.2. Market Share & Forecast
        • 6.2.4.1.2.1. By Technology
        • 6.2.4.1.2.2. By Application
        • 6.2.4.1.2.3. By End user
      • 6.2.4.2. Canada Cell Reprogramming Market Outlook
        • 6.2.4.2.1. Market Size & Forecast
        • 6.2.4.2.1.1. By Value
        • 6.2.4.2.2. Market Share & Forecast
        • 6.2.4.2.2.1. By Technology
        • 6.2.4.2.2.2. By Application
        • 6.2.4.2.2.3. By End user
      • 6.2.4.3. Mexico Cell Reprogramming Market Outlook
        • 6.2.4.3.1. Market Size & Forecast
        • 6.2.4.3.1.1. By Value
        • 6.2.4.3.2. Market Share & Forecast
        • 6.2.4.3.2.1. By Technology
        • 6.2.4.3.2.2. By Application
        • 6.2.4.3.2.3. By End user

7. Europe Cell Reprogramming Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Technology
    • 7.2.2. By Application
    • 7.2.3. By End user
    • 7.2.4. By Country
      • 7.2.4.1. France Cell Reprogramming Market Outlook
        • 7.2.4.1.1. Market Size & Forecast
        • 7.2.4.1.1.1. By Value
        • 7.2.4.1.2. Market Share & Forecast
        • 7.2.4.1.2.1. By Technology
        • 7.2.4.1.2.2. By Application
        • 7.2.4.1.2.3. By End user
      • 7.2.4.2. Germany Cell Reprogramming Market Outlook
        • 7.2.4.2.1. Market Size & Forecast
        • 7.2.4.2.1.1. By Value
        • 7.2.4.2.2. Market Share & Forecast
        • 7.2.4.2.2.1. By Technology
        • 7.2.4.2.2.2. By Application
        • 7.2.4.2.2.3. By End user
      • 7.2.4.3. United Kingdom Cell Reprogramming Market Outlook
        • 7.2.4.3.1. Market Size & Forecast
        • 7.2.4.3.1.1. By Value
        • 7.2.4.3.2. Market Share & Forecast
        • 7.2.4.3.2.1. By Technology
        • 7.2.4.3.2.2. By Application
        • 7.2.4.3.2.3. By End user
      • 7.2.4.4. Italy Cell Reprogramming Market Outlook
        • 7.2.4.4.1. Market Size & Forecast
        • 7.2.4.4.1.1. By Value
        • 7.2.4.4.2. Market Share & Forecast
        • 7.2.4.4.2.1. By Technology
        • 7.2.4.4.2.2. By Application
        • 7.2.4.4.2.3. By End user
      • 7.2.4.5. Spain Cell Reprogramming Market Outlook
        • 7.2.4.5.1. Market Size & Forecast
        • 7.2.4.5.1.1. By Value
        • 7.2.4.5.2. Market Share & Forecast
        • 7.2.4.5.2.1. By Technology
        • 7.2.4.5.2.2. By Application
        • 7.2.4.5.2.3. By End user

8. Asia Pacific Cell Reprogramming Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Technology
    • 8.2.2. By Application
    • 8.2.3. By End user
    • 8.2.4. By Country
      • 8.2.4.1. China Cell Reprogramming Market Outlook
        • 8.2.4.1.1. Market Size & Forecast
        • 8.2.4.1.1.1. By Value
        • 8.2.4.1.2. Market Share & Forecast
        • 8.2.4.1.2.1. By Technology
        • 8.2.4.1.2.2. By Application
        • 8.2.4.1.2.3. By Technology
      • 8.2.4.2. India Cell Reprogramming Market Outlook
        • 8.2.4.2.1. Market Size & Forecast
        • 8.2.4.2.1.1. By Value
        • 8.2.4.2.2. Market Share & Forecast
        • 8.2.4.2.2.1. By Technology
        • 8.2.4.2.2.2. By Application
        • 8.2.4.2.2.3. By End user
      • 8.2.4.3. South Korea Cell Reprogramming Market Outlook
        • 8.2.4.3.1. Market Size & Forecast
        • 8.2.4.3.1.1. By Value
        • 8.2.4.3.2. Market Share & Forecast
        • 8.2.4.3.2.1. By Technology
        • 8.2.4.3.2.2. By Application
        • 8.2.4.3.2.3. By End user
      • 8.2.4.4. Japan Cell Reprogramming Market Outlook
        • 8.2.4.4.1. Market Size & Forecast
        • 8.2.4.4.1.1. By Value
        • 8.2.4.4.2. Market Share & Forecast
        • 8.2.4.4.2.1. By Technology
        • 8.2.4.4.2.2. By Application
        • 8.2.4.4.2.3. By End user
      • 8.2.4.5. Australia Cell Reprogramming Market Outlook
        • 8.2.4.5.1. Market Size & Forecast
        • 8.2.4.5.1.1. By Value
        • 8.2.4.5.2. Market Share & Forecast
        • 8.2.4.5.2.1. By Technology
        • 8.2.4.5.2.2. By Application
        • 8.2.4.5.2.3. By End user

9. South America Cell Reprogramming Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Technology
    • 9.2.2. By Application
    • 9.2.3. By End user
    • 9.2.4. By Country
      • 9.2.4.1. Brazil Cell Reprogramming Market Outlook
        • 9.2.4.1.1. Market Size & Forecast
        • 9.2.4.1.1.1. By Value
        • 9.2.4.1.2. Market Share & Forecast
        • 9.2.4.1.2.1. By Technology
        • 9.2.4.1.2.2. By Application
        • 9.2.4.1.2.3. By End user
      • 9.2.4.2. Argentina Cell Reprogramming Market Outlook
        • 9.2.4.2.1. Market Size & Forecast
        • 9.2.4.2.1.1. By Value
        • 9.2.4.2.2. Market Share & Forecast
        • 9.2.4.2.2.1. By Technology
        • 9.2.4.2.2.2. By Application
        • 9.2.4.2.2.3. By End user
      • 9.2.4.3. Colombia Cell Reprogramming Market Outlook
        • 9.2.4.3.1. Market Size & Forecast
        • 9.2.4.3.1.1. By Value
        • 9.2.4.3.2. Market Share & Forecast
        • 9.2.4.3.2.1. By Technology
        • 9.2.4.3.2.2. By Application
        • 9.2.4.3.2.3. By End user

10. Middle East & Africa Cell Reprogramming Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Technology
    • 10.2.2. By Application
    • 10.2.3. By End user
    • 10.2.4. By Country
      • 10.2.4.1. South Africa Cell Reprogramming Market Outlook
        • 10.2.4.1.1. Market Size & Forecast
        • 10.2.4.1.1.1. By Value
        • 10.2.4.1.2. Market Share & Forecast
        • 10.2.4.1.2.1. By Technology
        • 10.2.4.1.2.2. By Application
        • 10.2.4.1.2.3. By End user
      • 10.2.4.2. Saudi Arabia Cell Reprogramming Market Outlook
        • 10.2.4.2.1. Market Size & Forecast
        • 10.2.4.2.1.1. By Value
        • 10.2.4.2.2. Market Share & Forecast
        • 10.2.4.2.2.1. By Technology
        • 10.2.4.2.2.2. By Application
        • 10.2.4.2.2.3. By End user
      • 10.2.4.3. UAE Cell Reprogramming Market Outlook
        • 10.2.4.3.1. Market Size & Forecast
        • 10.2.4.3.1.1. By Value
        • 10.2.4.3.2. Market Share & Forecast
        • 10.2.4.3.2.1. By Technology
        • 10.2.4.3.2.2. By Application
        • 10.2.4.3.2.3. By End user

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Recent Development
  • 12.2. Mergers & Acquisitions
  • 12.3. Technology Launches

13. Competitive Landscape

  • 13.1. Allele Biotechnology co. ltd.
  • 13.2. ALSTEM, INC
  • 13.3. Applied Biological Materials Inc.
  • 13.4. Axol Bioscience Ltd.
  • 13.5. Fujifilm Cellular Dynamics inc.
  • 13.6. Lonza Group AG
  • 13.7. Mogrify inc.
  • 13.8. REPROCELL Inc.
  • 13.9. Stemnovate Limited
  • 13.10.Thermo Fisher Scientific Inc.

14. Strategic Recommendations

15. About us & Disclaimer